| Drug Name |
Ferrosoferric oxide |
| Drug ID |
BADD_D00886 |
| Description |
Ferumoxytol is an intravenously administered iron preparation indicated in the EU and the US for the treatment of iron deficiency anemia in adult patients with chronic kidney disease (CKD) [A32478].
It is comprised of superparamagnetic iron oxide nanoparticles which are coated by a semi-synthetic carbohydrate shell in an isotonic, neutral pH solution that may be administered at relatively high dose by rapid intravenous injection [L2181]. |
| Indications and Usage |
This drug is indicated for the treatment of iron deficiency anemia in adult patients who have experienced intolerance to oral iron or have experienced an unsatisfactory response to oral iron or
who have chronic kidney disease (CKD) [FDA label]. |
| Marketing Status |
approved; investigational |
| ATC Code |
Not Available |
| DrugBank ID |
DB06215
|
| KEGG ID |
D04177; D09142
|
| MeSH ID |
D052203
|
| PubChem ID |
14789
|
| TTD Drug ID |
D06CTM
|
| NDC Product Code |
69766-104; 0781-3154; 59338-775; 42973-331 |
| UNII |
XM0M87F357
|
| Synonyms |
Ferrosoferric Oxide | Oxide, Ferrosoferric | Ferriferrous Oxide | Oxide, Ferriferrous | Magnetite | Feraheme | Ferumoxytol |
